Drugs / AMNIOGEN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06704893 | Oct 2024 → Dec 2027 expected | osteoarthritis, knee | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04599673 | Oct 2020 → Sep 2021 | rotator cuff syndrome | Kaohsiung Veterans General Hospital. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMNIOGEN | “AMNIOGEN® 40mg (HCT Regenerative, New Taipei, Taiwan) was diluted in 3.0 mL of sterile normal saline.” NCT06704893 ↗ |
| Modality | Other / unclassified | “AmnioGen® amnion matrix allograft is a bioactive tissue matrix” NCT04599673 ↗ |
| Route | Other | “Participants will receive intra-articular knee injections under ultrasound guidance with AMNIOGEN® 40mg” NCT06704893 ↗ |